Alkermes (NASDAQ:ALKS) will be releasing its earnings data before the market opens on Wednesday, February 14th. Analysts expect Alkermes to post earnings of $0.13 per share for the quarter.

Shares of Alkermes (ALKS) opened at $53.89 on Monday. The company has a current ratio of 3.05, a quick ratio of 2.72 and a debt-to-equity ratio of 0.23. Alkermes has a 12-month low of $46.42 and a 12-month high of $64.04. The company has a market capitalization of $8,290.00, a price-to-earnings ratio of -48.55 and a beta of 1.94.

In other news, Director Paul J. Mitchell sold 1,000 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $51.98, for a total value of $51,980.00. Following the transaction, the director now owns 9,000 shares of the company’s stock, valued at $467,820. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP James M. Frates sold 20,932 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $50.51, for a total value of $1,057,275.32. Following the completion of the transaction, the senior vice president now directly owns 164,971 shares in the company, valued at approximately $8,332,685.21. The disclosure for this sale can be found here. Insiders sold 135,485 shares of company stock worth $8,227,502 in the last ninety days. Corporate insiders own 5.34% of the company’s stock.

Several research analysts have issued reports on ALKS shares. Credit Suisse Group set a $66.00 target price on Alkermes and gave the stock a “buy” rating in a research report on Tuesday, November 28th. Zacks Investment Research raised Alkermes from a “hold” rating to a “buy” rating and set a $61.00 target price on the stock in a research report on Monday, January 8th. Barclays cut Alkermes from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $66.00 to $50.00 in a research report on Monday, October 16th. JPMorgan Chase & Co. set a $78.00 target price on Alkermes and gave the stock a “buy” rating in a research report on Friday, October 27th. Finally, UBS Group set a $54.00 target price on Alkermes and gave the stock a “hold” rating in a research report on Friday, October 27th. Eight research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $64.17.

COPYRIGHT VIOLATION WARNING: This report was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://theolympiareport.com/2018/02/12/alkermes-alks-set-to-announce-quarterly-earnings-on-wednesday.html.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Earnings History for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.